JP2024520395A5 - - Google Patents
Info
- Publication number
- JP2024520395A5 JP2024520395A5 JP2023572622A JP2023572622A JP2024520395A5 JP 2024520395 A5 JP2024520395 A5 JP 2024520395A5 JP 2023572622 A JP2023572622 A JP 2023572622A JP 2023572622 A JP2023572622 A JP 2023572622A JP 2024520395 A5 JP2024520395 A5 JP 2024520395A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylene
- halogens
- cycloalkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163193243P | 2021-05-26 | 2021-05-26 | |
| US63/193,243 | 2021-05-26 | ||
| PCT/US2022/030839 WO2022251302A1 (en) | 2021-05-26 | 2022-05-25 | Substituted fused bicyclic macrocyclic compounds and related methods of treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520395A JP2024520395A (ja) | 2024-05-24 |
| JP2024520395A5 true JP2024520395A5 (cg-RX-API-DMAC7.html) | 2024-12-27 |
Family
ID=82851881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023572622A Pending JP2024520395A (ja) | 2021-05-26 | 2022-05-25 | 置換される縮合二環式大環状化合物および関連のある治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240182491A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4347046A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024520395A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117999265A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022281345A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3219506A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022251302A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4680611A1 (en) | 2023-03-16 | 2026-01-21 | Takeda Pharmaceutical Company Limited | Macrocyclic heterocycle compounds and use thereof |
| JP2026518313A (ja) | 2023-06-01 | 2026-06-04 | ハー・ルンドベック・アクチエゼルスカベット | スピロ大環状オレキシン2受容体アゴニスト |
| CN122374291A (zh) | 2023-12-12 | 2026-07-10 | 爱杜西亚药品有限公司 | 作为食欲素受体调节剂的芳基砜及砜酮衍生物 |
| WO2025132542A1 (en) | 2023-12-19 | 2025-06-26 | Idorsia Pharmaceuticals Ltd | Macrocyclic orexin agonists |
| WO2026017128A1 (zh) * | 2024-07-17 | 2026-01-22 | 江苏恩华药业股份有限公司 | 作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途 |
| US20260109711A1 (en) * | 2024-09-18 | 2026-04-23 | Vertex Pharmaceuticals Incorporated | Macrocyclic sulfonamide modulators |
| US20260144795A1 (en) | 2024-11-27 | 2026-05-28 | H. Lundbeck A/S | Spiromacrocyclic orexin 2 receptor agonists |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8258163B2 (en) | 2008-06-04 | 2012-09-04 | Board Of Regents, The University Of Texas System | Small-molecule agonists for type-2 orexin receptor |
| WO2014198880A1 (en) | 2013-06-14 | 2014-12-18 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
| US20160250224A1 (en) | 2013-09-24 | 2016-09-01 | The Board Of Regents Of The University Of Texas System | Orexin-control of bone formation and loss |
| WO2015073707A1 (en) | 2013-11-15 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating heart failure with agonists of hypocretin receptor 2 |
| SG11201604639YA (en) | 2013-12-12 | 2016-07-28 | Univ Tsukuba | Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof |
| JP6552117B2 (ja) | 2014-03-28 | 2019-07-31 | 国立大学法人 筑波大学 | 敗血症の予防治療剤 |
| SG11201806429PA (en) * | 2016-02-04 | 2018-08-30 | Takeda Pharmaceuticals Co | Substituted piperidine compound and use thereof |
| WO2018053302A1 (en) * | 2016-09-19 | 2018-03-22 | Ensemble Therapeutics Corporation | Macrocyclic compounds for the inhibition of indoleamine-2,3-dioxygenase activity and use thereof |
| MA47233A (fr) * | 2016-12-19 | 2019-10-23 | Epizyme Inc | Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation |
| US11319286B2 (en) * | 2017-08-03 | 2022-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| US10428023B2 (en) | 2017-08-03 | 2019-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| CN110156813B (zh) * | 2018-02-13 | 2023-07-25 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| CN110627812B (zh) * | 2018-06-25 | 2022-10-11 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| EP3816154B1 (en) * | 2018-06-29 | 2025-04-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| US11098029B2 (en) * | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| KR20260083444A (ko) * | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| EP4247801A4 (en) * | 2020-11-23 | 2024-10-30 | Merck Sharp & Dohme LLC | 3-AMINO PYRROLIDINE AND MACROCYCLIC PIPERIDINE OREXIN RECEPTOR AGONISTS |
| US12006330B2 (en) * | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
-
2022
- 2022-05-25 AU AU2022281345A patent/AU2022281345A1/en active Pending
- 2022-05-25 EP EP22754192.7A patent/EP4347046A1/en active Pending
- 2022-05-25 WO PCT/US2022/030839 patent/WO2022251302A1/en not_active Ceased
- 2022-05-25 CA CA3219506A patent/CA3219506A1/en active Pending
- 2022-05-25 CN CN202280047653.8A patent/CN117999265A/zh active Pending
- 2022-05-25 JP JP2023572622A patent/JP2024520395A/ja active Pending
-
2023
- 2023-11-14 US US18/389,260 patent/US20240182491A1/en active Pending